My bad: I left out Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As we were finishing last week’s issue of The Cancer Letter, I had a lingering fear that my story about cancer centers bifurcating the job of the cancer center director would miss an institution or two.

In the story, I listed NCI-designated cancer centers where the top job is split into two: 

  1. the chief executive, and 
  2. the principal investigator on the NCI Cancer Center Support Grant.

I counted seven such institutions (The Cancer Letter, April 5, 2024). 

And I missed Fox Chase Cancer Center! 

So, the right number is eight. I think  changes that occurred in eight out of 72 NCI-designated cancer centers can be declared a trend. 

How could I have missed Fox Chase, considering that I spoke with top officials at that institution during the 2021 interregnum

To report this story, I had to rely on the oral tradition, always a hazardous path. In fact, even some of the institutions that split the two positions weren’t sure when they did so. 

Here is the updated list, with Fox Chase highlighted:

  • At St. Jude Children’s Research Hospital, two roles were split in 2004 when William Evans succeeded Art Nienhuis as CEO. Evans decided to separate the two roles “because the roles and responsibilities of the CEO had grown so much and the expectations for the CCSG PI were growing as well,” said Michael B. Kastan, who took responsibility over St. Jude’s CCSG at the time. Kastan is now the executive director of Duke Cancer Institute. James R. Downing now serves as St. Jude’s CEO and Charles W.M. Roberts serves as the center director.
  • At Moffitt Cancer Center, this change occurred in 2012. Now, the CEO job is held by Patrick Hwu, and the jobs of the executive vice president, center director, and chief scientific officer are held by John L. Cleveland
  • At City of Hope, the CEO-director split occurred in 2013. Since that time, the CEO position has been held by Robert W. Stone, and the center director and chief scientific officer job is now held by John D. Carpten.
  • At The Ohio State University Comprehensive Cancer Center, the change occurred in 2017. The interim CEO is now David E. Cohn, and the center director is Raphael E. Pollock
  • At Huntsman Cancer Institute at the University of Utah, the two roles were split in 2018. The CEO job is now held by the long-time director Mary C. Beckerle and the center director job is held by Cornelia M. Ulrich
  • At Fox Chase, the job was split up in 2021, with Robert Uzzo becoming the president and CEO and Jonathan Chernoff becoming the center director.
  • At MD Anderson, the change was made earlier this year, in February. Peter WT Pisters now serves as the institution’s president, and Giulio F. Draetta, a senior vice president and the chief scientific officer, oversees the NCI core grant. 
  • At Oregon Health and Science University’s Knight Cancer Institute, the two jobs were split up earlier this year, with Brian J. Druker becoming the CEO, Thomas A. Sellers becoming the center director. 
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login